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Abstract 
Sacral neuromodulation (SNM) has emerged as a treatment option for refractory lower urinary 
tract and bowel dysfunction in children.  SNM is typically reserved for a select population of 
children who have failed an extended period of behavioral modification, biofeedback, and 
pharmacologic therapy.  The surgical techniques for SNM in children are analogous to those in 
adults and include both one- and two-stage procedures as well as a peripheral nerve evaluation 
with the InterStim® system (Medtronic, Minneapolis, MN).  Most studies have observed an 
improvement in symptoms and quality of life in children undergoing SNM for non-neurogenic 
and neurogenic lower urinary tract dysfunction but also a much higher reoperative rate than in 
adults.  Further high-quality research is necessary to corroborate the results of earlier studies and 
to better define the indications for SNM in children. 
 
Introduction 
Sacral neuromodulation (SNM) has developed a growing interest for the treatment of refractory 
lower urinary tract dysfunction (LUTD) over the past 20 years.  The Food and Drug 
Administration (FDA) initially approved the use of SNM with an implantable pulse generator 
(IPG) for the treatment of urgency urinary incontinence in 1997 followed by urgency-frequency 
syndrome and chronic non-obstructive urinary retention in 1999.  Concurrent with its expanding 
indications in adults, SNM has emerged as a treatment option for refractory LUTD in children.  
Off-label use of SNM has been most thoroughly investigated in children with refractory 
dysfunctional voiding and also been reported in children with neurogenic LUTD and bowel 
dysfunction.  In this review, we provide a critical evaluation of the literature and discuss the role 
of SNM in children with non-neurogenic and neurogenic LUTD. 
 Mechanism of Action 
The exact mechanism of action for SNM is not completely understood.  Our current knowledge 
is founded on the neurophysiologic pathways for storage and emptying of the bladder in animal 
models.  Proposed mechanisms of action are based on the selective excitation of somatic afferent 
fibers from the bladder, leading to the modulation of sacral and suprasacral reflexes that promote 
storage and emptying of the bladder.  For overactive bladder, the excitation of these somatic 
afferent fibers is thought to suppress the micturition reflex at the sacral level and via the 
ascending pathways to the pontine micturition center.  Inhibition at the sacral and supraspinal 
levels prevents the involuntary contraction of detrusor muscle, while still allowing for voluntary 
voiding due to selective avoidance of somatic afferent input from Aδ fibers.  Alternatively, the 
excitation of these somatic afferent fibers is thought to suppress the guarding reflex via the 
ascending pathways to the pontine micturition center and cortex for detrusor-external sphincter 
dyssynergia [1]. 
 
Evaluation 
In addition to a thorough history and physical examination, a variety of diagnostic tools are 
available and should be considered for the evaluation of children with LUTD, including a 
bladder and bowel diary, validated questionnaires, urinalysis, renal and bladder ultrasound, and 
uroflowmetry with a post-void residual volume and with or without electromyography of 
perineal muscles.  Urodynamic evaluation and additional imaging studies, such as a voiding 
cystourethrogram or spinal magnetic resonance imaging (MRI), should be considered in the 
evaluation of children with non-neurogenic LUTD, particularly when an invasive treatment like 
SNM is being considered [2, 3].  We routinely perform a videourodynamic evaluation and 
lumbosacral MRI on all children considered for SNM to characterize bladder dynamics and rule 
out correctable anatomic abnormalities (e.g. vesicoureteral reflux, bladder diverticula), occult 
neurogenic LUTD, and/or tethered spinal cord.  MRI is contraindicated in children with an 
implanted device and therefore cannot be reserved for those who fail SNM. 
 
Initial Management 
For children with neurogenic LUTD, the storage of urine at a low intravesical pressure is 
essential for preservation of renal function and achievement of urinary continence.  The mainstay 
of therapy includes early initiation of clean intermittent catheterization (CIC) and antimuscarinic 
therapy [6].  Off-label use of intravesical botulinum toxin A has proven to be effective and well 
tolerated in children with neurogenic LUTD, achieving urinary continence in 65-87% of children 
as well as reducing the mean maximum detrusor pressure to <40 cm H2O and increasing the 
compliance to >20 mL/cm H2O in most studies [7].  Enterocystoplasty remains the gold standard 
for children with a low-capacity, poorly compliant, and/or overactive bladder, who fail a 
conservative approach.  Children with reduced outflow resistance may also require a 
concomitant procedure at the bladder neck for achievement of urinary continence [6]. 
Overactive bladder is characterized by urinary urgency and often accompanied by 
frequency with or without incontinence, while dysfunctional voiding is characterized by the 
habitual contraction of the urethral sphincter and/or pelvic floor during voiding.  Dysfunctional 
voiding manifests as urinary frequency, urgency, incomplete emptying, and/or recurrent urinary 
tract infections and may significantly impact quality of life (QOL).  All of these conditions are 
idiopathic without identifiable underlying pathology [3].  Their initial management includes 
behavioral modification, initiation of a timed voiding regimen, and treatment of constipation.  
Biofeedback and/or pharmacologic therapy is typically offered as the next line of therapy.  
Antimuscarinic therapy has proven to be effective and well tolerated for the treatment of 
overactive bladder, and the off-label use of selective α-adrenergic blockers has been promising 
for the treatment of dysfunctional voiding in several small, uncontrolled studies [4].  Off-label 
use of intravesical botulinum toxin A has also been investigated for the treatment of overactive 
bladder and detrusor-external sphincter dyssynergia in children.  Preliminary results have been 
encouraging but require further investigation [5].  Several centers have developed a 
comprehensive program with a step-wise approach to the treatment of voiding dysfunction and 
achieved a success rate of 90% to 100% with behavioral modification, initiation of a regular 
voiding regimen, biofeedback, and/or pharmacologic therapy [4]. 
 
Indications 
SNM is considered a last option for a select population of children with refractory LUTD due to 
its expense and invasive nature.  Its off-label use has been investigated in children with 
overactive bladder, dysfunctional voiding, neurogenic LUTD, and bowel dysfunction.  Currently, 
the indications for SNM have not been well defined in children [8]. 
Based on our experience and current literature, SNM should only be considered in 
children who have failed an extended period of behavioral modification, biofeedback, and 
pharmacologic therapy [9-15].  Several groups have also offered intravesical botulinum toxin A, 
transcutaneous electrical nerve stimulation, and percutaneous tibial nerve stimulation to this 
population of children but have not required them to fail these less invasive therapies prior to 
SNM [13, 15]. 
There are no absolute contraindications to SNM.  Several groups have excluded children 
with neurologic diseases or spinal deformities in their series [10, 11, 14, 15].  Significant spinal 
deformities may complicate or even prohibit lead placement in the foramen of the third sacral 
spinal nerve (S3).  Various implanted components of the InterStim® system may also be affected 
by or affect the following:  cardiac devices, electrocautery, defibrillators, ultrasonic equipment, 
radiation therapy, magnetic resonance imaging, and theft detectors/screening devices [16]. 
Nearly all children require a two-stage procedure, allowing for a trial of variable duration 
(2-3 weeks) to determine whether they will benefit from IPG implantation.  Certain groups have 
required an objective symptomatic improvement during the trial, whereas others have made a 
subjective determination or not reported their criteria to undergo IPG implantation in their series 
[10, 11, 13-15].  There are no established criteria for a successful trial.  Dwyer et al. required at 
least a 50% symptomatic improvement in a bladder and bowel diary when compared to a 
preoperative diary [15].  Alternatively, Groen et al. required at least a 50% decrease in the 
episodes of urinary incontinence, post-void residual volume, need for CIC, and frequency in their 
series [13]. 
 
Surgical Techniques 
The surgical techniques for SNM in children are analogous to those in adults.  The InterStim® 
system (Medtronic, Minneapolis, MN) is the only commercially available implantable device for 
SNM.  Both one- and two-stage procedures have been described in children [9, 15, 17].  The 
one-stage procedure involves the simultaneous implantation of the lead and IPG after eliciting a 
neurologic response to the stimulation of S3 (Table 1), while the two-stage procedure involves 
lead implantation and connection to an external pulse generator followed by staged IPG 
implantation after a successful trial.  As an alternative to the first-stage procedure, a peripheral 
nerve evaluation (PNE) involves the implantation of a thin, flexible wire and connection to an 
external pulse generator under local anesthesia in an office-based setting.  PNE may be feasible 
in older, more mature children but rarely is a viable option in the pediatric population. 
The spinal foramena are often smaller and closer together in children than adults.  
Furthermore, the lead excursion (distance of lead activity) is typically reduced due to the smaller 
size of nerves and nerve roots, making proper lead placement more technically challenging.  A 
low threshold (<1 amp) is desired across all leads but may only be possible in up to 3 leads in 
smaller children.  A tine may also be exposed in smaller children but will be buried once the lead 
is tunneled. 
 
Clinical Evidence – Efficacy 
Non-neurogenic LUTD 
Several studies have demonstrated an improvement in symptoms and QOL in children 
undergoing SNM for non-neurogenic LUTD, but comparison is difficult due to heterogeneous 
cohorts and variable outcomes [10, 11, 13-15].  The most comprehensive series included 105 
consecutive children with a median age of 8 years (range, 6-16), who underwent either a one- or 
two-stage procedure for refractory dysfunctional elimination syndrome (DES) with a median 
follow-up of 2.72 years (range, 0.01-9.63).  A large proportion of children (42%) previously 
underwent a bladder or urethral procedure in their series, including 9 children who failed 
intravesical injection of botulinum toxin A.  Almost all children (94%) experienced an 
improvement in at least 1 of the following symptoms after SNM:  urinary incontinence, 
constipation, frequency and/or urgency, and nocturnal enuresis.  Urinary incontinence, 
constipation, frequency and/or urgency, and nocturnal enuresis improved in 89 of 101 (88%), 73 
of 92 (79%), 54 of 81 (67%), and 59 of 89 (66%) of children, respectively, and resolved in 41 of 
101 (41%), 37 of 92 (40%), 23 of 81 (28%), and 25 of 89 (28%) children undergoing SNM, 
respectively [15].  Groen et al. observed a similar response rate in a retrospective study of 18 
consecutive children with a mean age of 15 years (range, 9-17), who underwent a two-stage 
procedure for refractory overactive bladder, DES, Fowler syndrome, and neurogenic bladder 
with a median follow-up of 11 months (range, 0.5-180.0).  A long-term full response (defined as 
100% satisfaction and greater than 90% objective improvement in at least 1 of the following 
criteria for implantation:  urinary incontinence, elevated postvoid residual volume, need to 
perform CIC, and frequency) was achieved in 6 of 15 (40%) children, whereas a long-term 
partial response (defined as satisfaction and 50-90% objective improvement in at least 1 criteria 
for implantation) was achieved in 5 of 15 (33%) children for a total response rate of 73% after 
SNM.  Children with urinary incontinence also experienced a significant decrease in the mean 
number of incontinent episodes (23.2 to 1.3), and children undergoing CIC experienced a 
significant decrease in the mean frequency of catheterization per day after SNM (5.2 to 2.0) [13].  
These studies largely relied on non-validated questionnaires or patient-reported bladder and 
bowel diaries, which are subjective and have inherent limitations [18]. 
In an effort to provide more objective evidence of improvement in both symptoms and 
QOL after SNM, Stephany et al. evaluated the health-related QOL of 14 children with a median 
age of 10 years (range, 5-17), who underwent a two-stage procedure for refractory LUTD with a 
median follow-up of 6 months (range, 0.5-15.0).  Health-related QOL was evaluated before and 
after SNM, using the validated Vancouver non-neurogenic LUTD/DES questionnaire and 
PedsQL 4.0 Generic Core Scale.  Median Vancouver non-neurogenic LUTD/DES scores 
significantly improved after SNM (23.0/52 to 10.5/52), and mean total scores for PedsQL 4.0 
Generic Core Scale (75.0/100 to 84.0/100) and subscores for psychosocial (70.6/100 to 81.4/100) 
but not physical (85.9/100 to 86.9/100) QOL significantly improved after SNM.  These 
improvements remained durable over limited follow-up.  Nighttime and daytime urinary 
incontinence, urgency, and fecal incontinence also significantly improved after SNM [14]. 
 No studies were randomized or included a matched control group.  Results may therefore 
be attributed to the placebo effect or maturation of their cohorts [10, 11, 13-15].  Dwyer et al. 
demonstrated that urinary frequency and/or urgency resolved in a significantly greater proportion 
of children who had a follow-up of at least 2.72 years (38% vs. 14%), although none of the other 
symptoms correlated with the duration of follow-up [15].  Furthermore, the generalizability of 
these studies is limited due to the heterogeneity of their cohorts.  Most children were labeled as 
having an exclusionary diagnosis of DES rather than subgrouped, according to the terminology 
from the Standardization Committee of the International Children’s Continence Society [10, 11, 
14, 15].  In the series by Groen et al., the subgrouping of LUTD allowed for a more meaningful 
determination of who would benefit from SNM.  Children with overactive bladder, DES, and 
Fowler syndrome seemed to experience an improvement after SNM, while those with neurogenic 
bladder did not [13]. 
 
Neurogenic LUTD 
Off-label use of SNM is more controversial in children with neurogenic LUTD.  Several 
European studies have investigated its use in this population with encouraging results [9, 12].  
Guys et al. performed a prospective randomized controlled trial of 42 children with urinary 
incontinence due to neurogenic LUTD, who underwent a one-stage procedure and were followed 
for a minimum of 12 months.  Most children (79%) had an underlying etiology of spina bifida.  
Inclusion criteria were at least 2 of the following:  duration of continence less than or equal to 90 
minutes, postvoid residual volume greater than 50% of functional bladder capacity, compliance 
less than 15 mL/cm H2O, intravesical or leak point pressure greater than 40 cm H2O, and 
detrusor overactivity with peak pressures greater than 40 cm H2O.  Those randomized to the 
control group were treated with antimuscarinic therapy and bulking agents for urinary 
incontinence and vesicoureteral reflux as needed.  A subjective improvement was observed in 
several children undergoing SNM, including improved bowel function in 9 children, resolution 
of urinary tract infections in 5 children, and improved bladder sensation in 6 children.  One child 
experienced a resolution of urinary incontinence but still required CIC after SNM.  A 
comparison of urodynamic parameters also identified a significantly increased leak point 
pressure but a significantly decreased functional bladder capacity in children undergoing SNM.  
For children undergoing SNM, the compliance and functional bladder capacity were significantly 
improved on urodynamic evaluation at 6 and 9 but not 12 months when compared to baseline.  
Furthermore, the total bladder capacity was increased on all urodynamic evaluations.  An 
improvement in detrusor stability was also achieved in 30% of children with detrusor 
overactivity.  The authors suggested that the neurologic lesions of children in their series were 
too severe to demonstrate a significant improvement after SNM [9]. 
Based on these promising results, Haddad et al. performed a prospective randomized 
controlled trial of 33 children undergoing SNM for neurogenic urinary and/or fecal incontinence 
at multiple centers in France.  All children underwent a one-stage procedure and were 
randomized to either the activation or deactivation of their device for 6 months and subsequently 
crossed over to the other group for 6 months with a washout period of 45 days.  Thirty percent of 
children had an underlying etiology of spina bifida with similar inclusion criteria to the prior 
study.  A response (defined as a resolution or greater than 50% improvement in the number of 
urinary and/or fecal incontinent episodes with a minimal need for protection) was achieved in 17 
of 21 (81%) children with urinary incontinence and 14 of 18 children (78%) with fecal 
incontinence.  Five children experienced a continued response after deactivation of their device, 
suggesting a permanent remodeling of neurophysiologic pathways [12].  Roth et al. reported a 
similar phenomenon in 2 children undergoing SNM for refractory DES [11].  Based on a 
crossover analysis, SNM was significantly more effective than conservative therapy for the 
treatment of both urinary and fecal incontinence.  A comparison of urodynamic parameters also 
identified a significantly increased cystometric bladder capacity (+24.27 mL vs. -37.45 mL) but a 
significantly greater amount of detrusor overactivity (+1 vs. -0.36) in children with SNM [12].  A 
consistent improvement in urodynamic parameters was not observed in children with SNM, as in 
the prior study [9, 12].  The authors suggested that a subjective improvement in symptoms may 
precede an objective improvement in urodynamic parameters [12].  Others have argued that the 
routine use of urodynamic evaluation may be unwarranted due to lack of correlation with 
symptomatology [18].  Stephany et al. recommended the limited use of urodynamic evaluation in 
children with non-neurogenic LUTD who have a poor response to SNM due to its invasive 
nature [14]. 
 The quality of these studies is superior to the evidence for children with non-neurogenic 
LUTD, given their randomization and inclusion of a control group or crossover design.  
However, the generalizability of these studies is still limited by their heterogeneous cohorts, 
which included a variety of neurologic diseases as well as congenital anorectal and urologic 
abnormalities [9, 12].  Nevertheless, SNM proved to be feasible and effective in children with 
neurogenic LUTD.  Neurologic diseases or spinal deformities have been considered a 
contraindication to SNM due to perceived difficulty with accessing the S3 foramen and 
presumed paucity of existing neurotransmission.  Haddad et al. were successfully able to place a 
lead in the S3 foramen in 33 of 41 children (81%) in their series and achieve a similar response 
rate to children with non-neurogenic LUTD [10-13, 15]. 
 
Bowel dysfunction 
While the use of SNM has been thoroughly investigated in adults with constipation and fecal 
incontinence, a paucity of evidence exists in children.  Bladder and bowel dysfunction should be 
evaluated concomitantly due to their close relationship and frequent co-occurrence in children 
[3].  Several studies have evaluated for improvement in bowel function in children undergoing 
SNM for refractory LUTD [9-12, 14, 15].  Dwyer et al. noted that most children (88%) suffered 
from both bladder and bowel dysfunction in their series and demonstrated an improvement in 
constipation in 79% of children undergoing SNM [15].  Stephany et al. also observed a 
significant improvement in fecal incontinence in 5 children undergoing SNM in their series [14].  
Haddad et al. achieved a similar response rate of 71% for children with neurogenic urinary 
and/or fecal incontinence undergoing SNM.  Incontinence was mixed in 19 of 33 (58%) children 
and fecal only in 5 of 33 (15%) children in their series, but a consistent improvement in 
rectomanometric parameters was not demonstrated in children with SNM [12].  Only 1 recent 
study has primarily focused on the use of SNM in children with bowel dysfunction.  This series 
included 13 girls with a median age of 15.2 years (range, 10-18), who underwent a two-stage 
procedure for refractory functional constipation and were followed for a minimum of 6 months.  
Most children (92%) experienced an improvement in constipation after SNM with a significant 
improvement in the Average Cleveland Clinic constipation score (20.9/30 to 8.4/30), frequency 
of defecation, abdominal pain, straining, and sensation of incomplete evacuation.  Absenteeism 
from school completely resolved after SNM, compared to an incidence of 77% preoperatively.  
Despite its retrospective design and the small size of its cohort, the preliminary results of this 
study are encouraging but require further investigation [19]. 
 
Clinical Evidence – Complications 
Complications rates in children undergoing SNM have ranged from 14% to 56% with the most 
common complications including:  pain at the site of implantation (0 – 15%), surgical site 
infection (SSI) (0 – 12%), lead migration or fracture (0 – 10%), IPG malfunction or its 
connection (0 – 9%), undesired sensation (0 – 8%), and seroma (0 – 4%) [9-15, 19]. 
 A majority of complications are managed with observation or device reprogramming in 
adults.  However, a much higher reoperative rate for revision, replacement, or explantation of the 
device (13 – 56%) has been observed in children undergoing SNM [9-15, 19].  In the study with 
the longest duration of follow-up, 85 reoperations were performed in 59 of 105 (56%) children 
for an average of 0.79 additional unplanned operations per child.  A total of 47 revisions or 
replacements were performed in 36 children at a median time of 1.26 years from their initial 
procedure (range, 0.01 – 6.25 years), and 38 explantations (22 due to resolution or stable 
improvement in symptoms) were performed in 36 children at a median time of 2.36 years (range, 
0.03 – 9.05 years) [15]. 
 Several technical considerations may decrease the risk of complications and reoperation 
in children.  The most recent model of IPG (InterStim® II neurostimulator, model 3058) is 37% 
smaller by volume and 50% lighter than the prior model as well as directly connects to the lead, 
eliminating the need for a quadripolar extension.  These modifications are important in children, 
who have less subcutaneous tissue in their gluteal region than adults.  The newer leads also 
consist of tines that are deployed for fixation rather than being anchored to the periosteum.  This 
modification may minimize lead migration during the trial, pain at the implantation site, and 
difficulty with revision or explantation [16].  Several authors have suggested a need to further 
miniaturize and redesign the device for children [12, 15, 18].  Another technical consideration is 
the decision to perform a one- or two-stage procedure.  A one-stage procedure prevents the 
accidental migration or removal of the lead during the trial and eliminates the need for a second 
anesthetic.  Dwyer et al. demonstrated a significantly decreased rate of explantation but no 
difference in the rate of SSI in children undergoing a one-stage procedure, although only a small 
number of children (15%) elected for this approach in their series [15]. 
 Lead migration or fracture due to somatic growth is unique to children.  Clark et al. 
observed an association between lead malfunction and somatic growth in 4 children undergoing 
SNM at a mean age of 12.1 years (range, 11-13.2).  Three children (75%) required a total of 5 
revisions due to lead malfunction with a mean time of 1.5 years (range, 0.7 – 2.8 years) and 
somatic growth of 8.1 cm (range, 4 – 12.5 cm) between revisions.  Efficacy was restored after 
replacing the lead in a similar position during all revisions.  Their reoperative rate was higher 
than other series, which was attributed to an increased pubertal growth due to the older age of 
children and absence of comorbidities in their cohort [20]. 
 
Conclusions 
A growing body of evidence supports the off-label use of SNM in children with refractory 
LUTD and bowel dysfunction.  Most studies have demonstrated an improvement in symptoms 
and QOL in children undergoing SNM for non-neurogenic and neurogenic LUTD but also a 
much higher reoperative rate than in adults [9-15, 19].  Comparison is difficult due to different 
designs, heterogeneous cohorts, and variable outcomes.  Higher quality evidence is needed, as 
most studies are retrospective and lack a randomized or matched control group. 
The use of SNM will continue to expand in children with refractory LUTD due to the 
challenging nature of treating this population.  Further research is necessary to corroborate the 
results of earlier studies and to better define the indications for SNM in children [8].  
Forthcoming studies should subgroup cohorts according to the terminology from the 
Standardization Committee of the International Children’s Continence Society and include a 
randomized or matched control group.  Researchers should strive to establish a uniform criterion 
for the definition of outcomes, using a variety of validated questionnaires and objective clinical 
data [3, 18].  Further research should also focus on the neurophysiologic pathways that promote 
the storage and emptying of the bladder, as this will facilitate the development of novel treatment 
options for LUTD in children. 
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Table 1.  Neurologic response to stimulation of sacral spinal nerves 
Sacral spinal nerve Motor – pelvic floor Motor – lower 
extremity 
Sensory 
S2 Anterior-posterior 
shortening of 
perineum (clamp), 
deepening and 
flattening of 
intergluteal fold 
(bellows) 
Rotation of hip, 
contraction of calf, 
rotation of heel, 
dorsiflexion of foot 
Genital 
S3 Bellows Dorsiflexion of great 
toe 
Genital, perineal, and 
anal 
S4 Bellows None Anal 
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